Icotidine, an antagonist of histamine at both H1 and H2 receptors.
SK&F 93319 (icotidine), 2-[4-(3-methoxypyrid-2-yl)butylamino]-5-[(6-methylpyrid-3-yl )-methyl]- pyrimidin-4-one trihydrochloride, has been identified as a novel agent which combines into one molecule the ability to antagonize the actions of histamine at H1 and H2 receptors across a similar concentration or dose range. The degree of antagonism of vascular responses to histamine exceeds that possible with either an H1- or H2-receptor histamine antagonist alone. SK&F 93319 may have therapeutic utility in conditions requiring simultaneous antagonism of histamine at H1 and H2 receptors.
D000818:Animals; D001980:Bronchi / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D005744:Gastric Acid / Q000378:metabolism; D006321:Heart / Q000187:drug effects; D006634:Histamine H1 Antagonists; D006635:Histamine H2 Antagonists; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D066298:In Vitro Techniques; D011725:Pyridines / Q000378:metabolism / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D014655:Vascular Resistance / Q000187:drug effects
D006634:Histamine H1 Antagonists; D006635:Histamine H2 Antagonists; D007093:Imidazoles; D011725:Pyridines; C043465:icotidine; C027703:oxmetidine